巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    CymaBay Therapeutics

    CBAY
    2.020
    0.050
    2.54%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・CymaBay Therapeutics - 延遲價格・最後更新於 27/05 8:25
    最高位
    2.030
    最低位
    1.930
    開市價
    --
    前收市價
    1.970
    成交量(千)
    18.10
    成交額(百萬)
    0.27
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    171.05
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    5.060 - 1.670
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    CymaBay Therapeutics
    證券代碼
    CBAY.US
    所屬板塊
    Biotechnology
    公司業務
    CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.
    發行量
    84677939
    公司總部
    7575 Gateway Boulevard, Suite 110
    公司網址
    https://www.cymabay.com
    公司電郵
    investors@cymabay.com
    公司電話
    +1 510 293-8800
    暫無內容

    關於

    CymaBay Therapeutics(CBAY.US)所屬的行業板塊為Biotechnology。
    CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.
    詳細公司背景可參考: https://www.cymabay.com